（来源：上观新闻） 在"家会"现场，这位"三全脑机接口"临床受试者不仅脑控设备参与抽红包环节，更用"意念"亲笔写 下"福"字，作为新年礼物赠予每一位脑虎员工。借助XessOs系统，受试者与大家聊天、互动、分享生 活，以平常而温暖的方式重新融入新春日常。 马年新春前夕，一位因高位截瘫卧床八年的患者，用"意念"写下"福"字，将它作为新年礼物，送给脑虎 科技的每一位员工。 2月12日，上海脑机接口头部企业脑虎科技举办了一场别开生面的内部"家会"。与往年不同，今年公司 的年度聚会没有繁复的节目流程，还邀请了一位特殊的"家人"——全球唯二、中国首例植入"全植入、 全无线、全功能"脑机接口的临床受试者，来到现场，与全体员工共聚团圆。 "我们问了员工最想要什么，答案很一致：实在的温暖，和陪伴家人的时间。"脑虎科技创始人兼首席科 学家陶虎说，为了让每位员工能更从容地安排返乡与团聚，公司调整了传统的年会形式，而这位临床受 试者的到来，成为整场"家会"最动人的注脚。 去年12月，在植入式柔性脑机接口领域处于领先地位的脑虎科技，发布了国内首款内置电池的全植入、 全无线、全功能脑机接口产品。依托自研的插件式脑机接口操作系统XessO ...

Core Viewpoint - The article highlights significant advancements in brain-machine interface (BMI) technology in China, showcasing breakthroughs in flexible electrode arrays and clinical applications, indicating a growing investment interest and market potential in this field [1][4][6]. Group 1: Technological Breakthroughs - A research team from Northwestern Polytechnical University has developed a three-dimensional conical carbon-based flexible cortical electrode array, addressing key issues such as brain tissue damage and poor biocompatibility, and achieving international space environment technology validation [1]. - The electrode shows hundreds of times improvement in key performance metrics compared to traditional metal electrodes, ensuring long-term safety and stability for clinical applications [1]. - The article notes that 2025 is referred to as the "year of the brain-machine interface" in China, with multiple clinical trials and innovations being reported [2]. Group 2: Investment and Market Growth - Investment enthusiasm in the BMI sector has surged, with 24 financing events recorded from January to November 2025, marking a 30% year-on-year increase, and total financing exceeding 10 billion yuan over the past five years [4]. - The "14th Five-Year Plan" has identified brain-machine interfaces as one of six future industries, indicating a strategic focus on this technology as a new engine for economic growth [4]. - The BMI market in China was valued at 3.2 billion yuan in 2024, with an 18.8% year-on-year growth, projected to reach 5.58 billion yuan by 2027, reflecting a 20% growth rate [6]. Group 3: Clinical Applications and Innovations - Ming Vision Brain Machine Technology has introduced an implantable BMI visual reconstruction system, offering new possibilities for visually impaired patients [5]. - The second invasive BMI clinical trial has achieved significant progress, transitioning from 2D screen control to 3D physical world interaction [5]. - Shanghai Brain Tiger Technology has successfully completed the first clinical trial of a fully implanted, wireless, and functional BMI product, emphasizing the technology's potential to connect life and hope [5]. Group 4: Stock Market Performance - Several BMI-related stocks have experienced significant declines, with 14 stocks showing over a 20% drop from their highs, including HaiGe Communication and PuLiTe [6][7]. - In terms of profit forecasts for 2025, nine BMI-related stocks are expected to see net profit growth, with notable increases for companies like BeiLu Pharmaceutical and LePu Medical [8].

Group 1 - The core point of the news is that Brain Tiger Technology has officially commenced construction of its "super factory" project in Jiangxi, which is a significant step towards the mass production and standardization of domestic brain-computer interface technology, expected to be completed and operational by the second half of 2026 [1][2]. Group 2 - The "super factory" will cover an area of approximately 14,300 square meters and will focus on three main industrial capabilities: establishing a mass production base for high-throughput implantable flexible electrodes, high-frequency electroencephalograms, surgical robots, and the first fully implanted, fully wireless, and fully functional brain-computer interface system, aiming for stable delivery of tens of thousands of units [2]. - The factory will serve as a "super data center," designed to drive continuous technological iteration by collecting, processing, and analyzing neural signal data, thereby optimizing algorithms and facilitating the development of next-generation products, creating an industrial ecosystem that deeply integrates brain-computer interfaces with artificial intelligence [2]. - Additionally, the factory will feature a "simulated life rehabilitation area," innovatively planning a one-stop rehabilitation training environment that closely replicates real-life and work scenarios, assisting patients with implanted brain-computer interfaces in efficiently rebuilding life skills and helping them return to society with dignity [2].

Core Insights - The article discusses the rapid advancement and commercialization of brain-computer interface (BCI) technology in China, driven by policy support and significant capital investment [1][5][9]. Technological Breakthroughs - Recent breakthroughs in BCI technology include successful clinical trials for invasive systems, enabling high-level paraplegic patients to control devices like smart wheelchairs and robotic dogs [5][6]. - Companies like JieTi Medical and ChipSmart have made significant progress, with JieTi completing three invasive clinical trials and ChipSmart's semi-invasive product achieving successful human implants [5][6]. - The BCI technology is categorized into non-invasive, semi-invasive, and invasive types, each with its advantages and disadvantages [5]. Policy and Capital Support - The Chinese government has identified BCI as one of the six future industries in the 14th Five-Year Plan, providing a strategic framework for its development [8][9]. - Recent policy initiatives include the establishment of independent billing for BCI services by the National Medical Insurance Administration, with several provinces setting clear pricing for BCI medical services [8][9]. - The National Medical Products Administration has also initiated standards for BCI technology, which will help reduce costs and risks associated with clinical applications [8][9]. Market Opportunities - The BCI market is expected to grow significantly, with a focus on medical applications for conditions like stroke, epilepsy, and paralysis, where patients show a strong willingness to adopt early products [6][7]. - The integration of BCI technology with artificial intelligence and robotics could open up a trillion-dollar market space in the long term [11]. Industry Standardization - The BCI industry is anticipated to move towards standardization and scalability, with initial industry standards expected to be established by 2027-2028 [10]. - The domestic BCI industry benefits from strong policy support, a vast clinical resource base, and a complete supply chain, which are crucial for its growth [10]. Investment Landscape - Investment firms highlight the dual nature of BCI as both a medical and technology investment, emphasizing the importance of identifying policy-supported "true BCI" targets [11]. - The potential for leading Chinese BCI companies to emerge on the global stage is significant, given the country's advancements in technology and supportive investment environment [11].

Core Insights - The brain-computer interface (BCI) industry in China is experiencing significant advancements, with clinical results emerging for high-level paraplegics and substantial funding rounds, including a recent 2 billion yuan investment in a non-invasive unicorn company, Strong Brain Technology, marking the second-largest funding record globally in this field [1][2] - The industry is poised for rapid commercialization, driven by technological breakthroughs, capital influx, and supportive policies, as it transitions from cutting-edge technology to practical applications in daily life [1][5] Technological Breakthroughs - Recent advancements in BCI technology include successful clinical trials for invasive systems, enabling high-level paraplegics to control smart wheelchairs and robotic dogs [2][3] - Companies like JieTi Medical and Chip Intelligence have made significant progress, with JieTi completing trials for its invasive BCI system and Chip Intelligence's semi-invasive product achieving human implantation [2][3] - The first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology has shown promising results, allowing an 8-year paraplegic patient to achieve thought control just five days post-surgery [2][3] Policy and Capital Support - The BCI sector benefits from comprehensive policy support, including its designation as one of the six future industries in the 14th Five-Year Plan, which elevates it to a national strategic priority [5][6] - Recent initiatives by the Sichuan provincial medical insurance bureau have established pricing for 82 neuro-related medical services, including BCI applications, facilitating clinical adoption [5][6] - The establishment of industry standards by the National Medical Products Administration is expected to lower costs and risks associated with technology development and clinical application [6] Industry Collaboration and Investment - Companies like Baiyang Pharmaceutical are actively collaborating with academic institutions to explore the integration of BCI with artificial intelligence, aiming for innovative clinical solutions [7] - Other listed companies are also engaging in the BCI space through material supply and equipment development, indicating a strong interest from institutional investors [7] Future Development and Challenges - The BCI industry is anticipated to move towards standardization and scalability, with initial industry standards expected to be established by 2027-2028 [8] - Potential constraints include the pace of chip design and production, as well as the need for ethical regulations regarding personal brain data [8] - Despite these challenges, the domestic BCI industry holds significant advantages, including strong policy support, a vast clinical resource base, and a comprehensive supply chain [8] Investment Opportunities - The BCI sector presents a dual investment opportunity in both medical and technological domains, with short-term focus on disease treatment and long-term potential for enhancing human capabilities through integration with AI and robotics [9] - The industry is positioned to cultivate leading global BCI companies, fostering a capital-innovation synergy between primary and secondary markets [9]

Core Viewpoint - The recent surge in the brain-computer interface (BCI) sector in the A-share market reflects a significant shift from laboratory research to clinical application, marking a milestone in the integration of life sciences and engineering technology [1] Group 1: Domestic Breakthroughs - The domestic BCI field has seen a rapid increase in clinical achievements, highlighted by Brain Tiger Technology's launch of the first fully implanted, wireless, and fully functional BCI product, which successfully enabled a high-level paraplegic patient to control web browsing through thought [2] - This "three-in-one" product addresses critical issues such as infection risks associated with external systems and allows patients to connect with various devices, creating an "extended body" ecosystem [2] - Clinical data shows that patients achieved thought control within five days post-surgery, with a decoding rate of 5.2 BPS, comparable to international standards [2] Group 2: Technological Advancements - The second-generation high-throughput wireless invasive BCI system developed by the Chinese Academy of Sciences allows high-level paraplegic patients to control wheelchairs and other devices using only their thoughts, with a fourfold increase in data reading speed [3] - The establishment of China's first comprehensive clinical trial area for BCIs signifies the standardization and scaling of clinical research in this field, providing ample clinical data support for technological iterations [3] Group 3: Industry Acceleration - The rapid advancements in domestic technology are fueled by a competitive global environment, exemplified by Neuralink's plans for large-scale production of BCI devices and significant reductions in surgical time and costs [4] - The shift from niche research to essential medical applications is driven by the need for effective treatments for patients with spinal cord injuries and other neurological conditions, marking a revolutionary breakthrough in life sciences [4] Group 4: Caution Amidst Enthusiasm - Despite the excitement in the capital markets, the BCI field is still in a critical phase of clinical validation, with significant challenges remaining before large-scale commercialization can be achieved [5] - The complexity of the human brain presents a major challenge for accurately capturing and interpreting neural signals, with projections indicating that recording from one million neurons may not be feasible until 2100 [5] Group 5: Long-term Value of Technological Progress - The stock market surge in the BCI sector represents a forward-looking vote of confidence in breakthroughs in life sciences technology, which has the potential to transform the lives of millions suffering from neurological diseases [6] - As China transitions from a follower to a competitor in the BCI field, ongoing clinical breakthroughs and technological innovations are paving the way for new possibilities in human health [6]

Group 1: Commercial Aerospace - China Aerospace Science and Technology Corporation's commercial rocket subsidiary increased its registered capital from 1 billion to 1.396 billion yuan, with a 77.6% increase in investment from the parent company [5] - Blue Arrow Aerospace is aiming to become the first publicly listed commercial rocket company, with the commercial aerospace sector expected to enter a golden development period [9] - The low-orbit satellite internet in China is set to enter mass launch construction in the second half of 2025, with significant acceleration in industry development anticipated by 2026 [11] Group 2: Brain-Computer Interface - The first fully implanted, wireless, and fully functional brain-computer interface product in China has successfully completed its first clinical trial [20] - The brain-computer interface industry is expected to reach a market size of over 10 billion USD by 2030, with companies like Haige Communication and Xiangyu Medical seeing significant stock price increases [22] - Xiangyu Medical is focusing on non-invasive rehabilitation and exploring invasive technologies, with plans to cover over 1,000 top-tier hospitals by 2026 [24] Group 3: Financial Sector - The National Financial Regulatory Administration has lowered risk factors for long-term holding assets, which is expected to cultivate patient capital and support technological innovation [30] - The financial sector is experiencing strong performance, with stocks like Zhina Compass seeing a significant increase in value due to market expectations of a bull market [31] Group 4: Intelligent Driving - Nvidia plans to test a driverless taxi service by 2027, indicating advancements in autonomous driving technology [33] - The first batch of L3 autonomous vehicles in China has begun large-scale road operation, with companies like Wanjite Technology benefiting from this trend [34] - The automatic driving technology is moving towards mass production applications, with companies like Haoen Automotive seeing stock price increases [36]

Market Overview - The three major indices collectively rose, with the Shanghai Composite Index reaching a ten-year high, closing up 1.5% [1] - Trading volume in the Shanghai and Shenzhen markets increased to 2.81 trillion yuan, up 260.2 billion yuan from the previous trading day [1] - Over 4,100 stocks rose, with 143 stocks hitting the daily limit, marking the second consecutive day of over 100 limit-up stocks [1] Sector Performance - The commercial aerospace sector showed strong activity, with over ten stocks hitting the daily limit, including Aerospace Huanyu and Beidou Star [2] - The registered capital of China Aerospace Science and Technology Corporation's commercial rocket subsidiary increased from 1 billion yuan to 1.396 billion yuan, a 77.6% increase [2] - The brain-computer interface sector continued its strong performance, with multiple stocks such as Sanbo Brain Science and Meihao Medical hitting the daily limit [2][3] - The financial sector saw a collective surge, with stocks like Huayin Securities and Dazhihui reaching the daily limit [3] Key Stocks - Notable stocks included Leike Defense with five consecutive limit-ups and Lushin Investment with six limit-ups in eight days [6] - The non-ferrous metals sector remained active, with companies like Zijin Mining and Luoyang Molybdenum hitting historical highs [6] Future Outlook - The market is expected to continue its upward trend, with the potential for further gains if trading volume remains strong [8] - However, the ability to attract sufficient incremental capital will be crucial for sustaining this momentum [8] - The commercial aerospace, brain-computer interface, non-ferrous metals, and financial sectors are highlighted as key areas to watch for ongoing activity [8]

Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [10]. Core Insights - Elon Musk announced on December 31, 2025, that his brain-computer interface company Neuralink will begin "mass production" of brain-computer interface devices in 2026, transitioning to a "more streamlined and almost fully automated surgical process" [2][6]. - The brain-computer interface market has significant growth potential, with invasive products expected to become a key focus area. Internationally, companies like Neuralink are leading in technology, while several domestic companies in China have made breakthroughs in R&D, supported by favorable policies [2]. - The global brain-computer interface market is projected to reach USD 2.62 billion by 2024, with a compound annual growth rate (CAGR) of 17.4% from 2025 to 2034. In China, the market is expected to exceed RMB 6 billion by 2028, with a CAGR of approximately 17.7% from 2024 to 2028 [14]. - Neuralink employs a minimally invasive implantation approach, with 12 individuals having implanted devices as of September 2025, totaling over 20,000 hours of usage [14]. - Several domestic companies have achieved breakthroughs in brain-computer interface technology, with notable advancements in clinical trials and regulatory approvals [14]. - The industry is encouraged by supportive policies, with the National Healthcare Security Administration in China having established pricing for brain-computer interface services [14]. - Experimental animals, such as mice and monkeys, play a crucial role in brain-computer interface research, with mice being used for initial testing and monkeys for more advanced validation due to their closer anatomical and functional similarities to humans [14]. - Recommended companies to watch include Meihao Medical for brain-computer interfaces and Zhaoyan New Drug for experimental animals [14].

Core Insights - The brain-computer interface (BCI) industry is entering a "golden development period," characterized by significant advancements from laboratory innovations to clinical applications [1][2][3] Group 1: Technological Advancements - In 2025, significant milestones were achieved in BCI technology, including the first clinical trials of flexible micro-invasive BCI systems and the first intervention-assisted trials for restoring limb function [2][3] - Three main technological routes are developing in parallel: invasive, semi-invasive, and non-invasive techniques, with invasive methods being central to medical rehabilitation due to their high signal acquisition precision [3][4] - The semi-invasive BCI system developed by Borui Kang Technology requires only a small hole in the skull for implantation, allowing patients to control movements through thought [4] Group 2: Clinical Applications and Breakthroughs - Clinical breakthroughs include the successful restoration of walking in patients with severe spinal cord injuries through innovative BCI technologies [3][4] - A variety of new BCI applications are emerging, such as a visual reconstruction system for visually impaired patients and a wireless, fully implanted BCI product that has completed its first clinical trial [10][11] Group 3: Industry Growth and Policy Support - The establishment of pricing regulations for BCI services by the National Medical Insurance Administration marks a significant step in integrating this technology into public healthcare [6][8] - Various regions, including Shanghai and the Guangdong-Hong Kong-Macau Greater Bay Area, are forming BCI innovation clusters to enhance industry capabilities and foster collaboration among enterprises, hospitals, and research institutions [7][8] Group 4: Future Prospects - Experts predict that 2026 will be a pivotal year for the BCI industry, with advancements in multi-disciplinary integration, clinical scalability, and diverse application scenarios [9][10] - The anticipated mass production of certain BCI devices will pave the way for a diversified application ecosystem, enhancing the potential for widespread commercial use [10][11]